Mineralys Therapeutics (MLYS) News Today $16.66 +0.56 (+3.48%) Closing price 04:00 PM EasternExtended Trading$16.75 +0.09 (+0.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Balyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Balyasny Asset Management L.P. acquired a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,786 shares of the company's sMay 21 at 3:35 AM | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular ProtectionMay 20 at 8:00 AM | globenewswire.comTema Etfs LLC Buys New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Tema Etfs LLC bought a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 89,529 shares of the company's stock, valued at approximately $1,102,000.May 20 at 6:16 AM | marketbeat.comDimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Dimensional Fund Advisors LP acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,412 shares of the company's stock, valued at approximately $202,000.May 20 at 3:15 AM | marketbeat.comPolar Asset Management Partners Inc. Has $1.22 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Polar Asset Management Partners Inc. lifted its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 144.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 99,100 shares of the cMay 19 at 5:52 AM | marketbeat.comSphera Funds Management LTD. Has $2.35 Million Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Sphera Funds Management LTD. lessened its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 30.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 190,672 shares of the company's stock after selling 81,800 shares during the periMay 18 at 6:55 AM | marketbeat.comWhat is HC Wainwright's Estimate for MLYS Q2 Earnings?May 17, 2025 | americanbankingnews.comMineralys at BofA Securities 2025: Lorundrostat’s Hypertension PromiseMay 16, 2025 | investing.comDavid Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMay 16, 2025 | insidertrades.comHC Wainwright Reaffirms "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)HC Wainwright reissued a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday.May 15, 2025 | marketbeat.comOrbimed Advisors LLC Sells 391,302 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Orbimed Advisors LLC reduced its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 19.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,611,637 shares of the company's stock after selling 391,302 shares durMay 15, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.23 EPSMineralys Therapeutics (NASDAQ:MLYS - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23.May 14, 2025 | marketbeat.comEarnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock risesMay 14, 2025 | uk.investing.comIntegral Health Asset Management LLC Buys 519,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Integral Health Asset Management LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 145.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 875,000 shares of the company's stock after purchasing an addMay 14, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comPositive Buy Rating for Lorundrostat Driven by Successful Trials and Future PotentialMay 13, 2025 | tipranks.comOptimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data ReleasesMay 13, 2025 | tipranks.comMineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 13, 2025 | finance.yahoo.comMineralys Therapeutics stock rises on better-than-expected Q1 resultsMay 13, 2025 | investing.comMineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call TranscriptMay 12, 2025 | seekingalpha.comMineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comMineralys Therapeutics to Present at Bank of America Health Care ConferenceMay 11, 2025 | msn.comUncovering Potential: Mineralys Therapeutics's Earnings PreviewMay 9, 2025 | benzinga.comMineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12May 7, 2025 | nasdaq.comMineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceMay 7, 2025 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025May 5, 2025 | globenewswire.comAdams Street Partners LLC Sells 402,847 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Adams Street Partners LLC lowered its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 26.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,129,807 shares of the company's stock after selling 402,84May 4, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Caligan Partners LPCaligan Partners LP increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,011,155 shares of the company's stock after acquiring an additional 30,May 3, 2025 | marketbeat.comMineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on ThursdayMineralys Therapeutics (NASDAQ:MLYS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-mineralys-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Hits New 52-Week High - Should You Buy?Mineralys Therapeutics (NASDAQ:MLYS) Hits New 52-Week High - Here's What HappenedMay 3, 2025 | marketbeat.comCarl Icahn Buys More Shares, and Tesla Insider Bucks the Selling TrendMay 1, 2025 | 247wallst.comMineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJMApril 28, 2025 | msn.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Increased by Boothbay Fund Management LLCBoothbay Fund Management LLC raised its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 650,023 shares of the company's stock after buying an adApril 28, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 6.2% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 6.2% - Here's WhyApril 27, 2025 | marketbeat.comMineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published studyApril 24, 2025 | msn.comMineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)April 23, 2025 | globenewswire.comJPMorgan Chase & Co. Purchases 482,174 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)JPMorgan Chase & Co. raised its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 2,251.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 503,590 shares of the company's stock after bApril 20, 2025 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Vanguard Group Inc. grew its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 5.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,432,042 shares of the company's stock after buyingApril 19, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Sees Large Growth in Short InterestMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 4,710,000 shares, a growth of 112.2% from the March 15th total of 2,220,000 shares. Currently, 12.7% of the company's stock are short sold. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.6 days.April 18, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $129,729.42 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a total transaction of $129,729.42. Following the sale, the chief financial officer now owns 215,340 shares of the company's stock, valued at approximately $2,597,000.40. This represents a 4.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.April 17, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells $165,147.98 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 11,366 shares of the firm's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $14.53, for a total transaction of $165,147.98. Following the completion of the sale, the insider now owns 111,686 shares of the company's stock, valued at $1,622,797.58. This trade represents a 9.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.April 17, 2025 | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells 15,319 Shares of StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 15,319 shares of the firm's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.19, for a total value of $186,738.61. Following the sale, the chief executive officer now directly owns 862,289 shares in the company, valued at approximately $10,511,302.91. This represents a 1.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.April 17, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Still a Buy?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Here's What HappenedApril 16, 2025 | marketbeat.comWellington Management Group LLP Boosts Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Wellington Management Group LLP raised its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 43.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,529 shares of the company's stock afteApril 15, 2025 | marketbeat.comInstitutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returnsApril 12, 2025 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.6% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 5.6% - What's Next?April 11, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Time to Sell?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - What's Next?April 10, 2025 | marketbeat.comADAR1 Capital Management LLC Increases Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)ADAR1 Capital Management LLC lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 15.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 841,541 shares of the company's stock after buying an additioApril 9, 2025 | marketbeat.comHC Wainwright Analysts Boost Earnings Estimates for MLYSMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Mineralys Therapeutics in a research report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings peApril 8, 2025 | marketbeat.comPrudential Financial Inc. Acquires 58,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Prudential Financial Inc. grew its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 85.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,650 shares of the companyApril 7, 2025 | marketbeat.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.960.65▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼154▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYTK News Today RYTM News Today PTCT News Today SRPT News Today RNA News Today SWTX News Today RARE News Today AKRO News Today ACLX News Today ZLAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
